Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested
Psoriasis Clinical Trials
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested
Dermatology Clinical Trials
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested
Pediatric Dermatology Clinical Trials
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested
A Randomized Trial of Induction Versus Expectant Management
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Elective Induction of Labor
Eligibility
Inclusion Criteria:
1. Nulliparous - no previous pregnancy beyond 20 weeks
2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age.
3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive
based on clinical information and evaluation of the earliest ultrasound.
Exclusion Criteria:
1. Project gestational age at date of first ultrasound is > 20 weeks 6 days
2. Plan for induction of labor prior to 40 weeks 5 days
3. Plan for cesarean delivery or contraindication to labor
4. Breech presentation
5. Signs of labor (regular painful contractions with cervical change)
6. Fetal demise or known major fetal anomaly
7. Heparin or low-molecular weight heparin during the current pregnancy
8. Placenta previa, accreta, vasa previa
9. Active vaginal bleeding greater than bloody show
10. Ruptured membranes
11. Cerclage in current pregnancy
12. Known oligohydramnios, defined as AFI < 5 or MVP < 2
13. Fetal growth restriction, defined as EFW < 10th percentile
14. Known HIV positivity because of modified delivery plan
15. Major maternal medical illness associated with increased risk for adverse pregnancy
outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac
disease, renal insufficiency)
16. Refusal of blood products
17. Participation in another interventional study that influences management of labor at
delivery or perinatal morbidity or mortality
18. Delivery planned elsewhere at a non-Network site
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cynthia Willson, RN, BSN
650-724-6372
I'm interested